Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 302
2024-516063-89-00Phase 3Authorised
- Sponsor
- Revolution Medicines
- Start
- Feb 2025
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing RMC-6236 with Investigator's choice standard of care (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Feb 2025; status: authorised.
02
Drugs
daraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516063-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516063-89-00.